¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦2Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ½ÉÆ÷Áö¾ö : 2022-06-12

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦2Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ½ÉÆ÷Áö¾ö : 2022-06-12
±³À°ÀÏÀÚ : 2022-06-12
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ½Å°ü2Ãþ Á¦¶ó´½È¦ ¿Ü 1°³È¦ (1Ãþ ·ÎÁ¸®È¦)  
±³À°ÁÖÁ¦ : Á¦2Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ  
´ã´çÀÚ : ¿À»óÈ£ ±³¼ö
¿¬¶ôó : 02-2228-2080  
À̸ÞÀÏ : ODDUNG9@yuhs.ac      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 09:10~09:25 Basic mechanisms regulating melanogenesis: Focus on PIH  ±èÁ¤Àº(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 09:25~09:40 Treatment of PIH in the real field: A to Z  Á¤º¸¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 09:40~09:55 Prevention of PIH: Tips for minimizing PIH after procedures?  ±èÀçÈ«(¿¬¼¼Á¶ÀºÇǺΰú) 
Åä·Ð 06-12 Á¦¶ó´½È¦ 09:55~10:05 Q&A  ±èÀ¯ÂùÀÌ»óÁرèÁ¤ÀºÁ¤º¸¿µ±èÀçÈ«(¾ÆÁÖÀÇ´ë¾Æ¸§´Ù¿î³ª¶óÇǺΰúÇѾçÀÇ´ëÇѸ²ÀǴ뿬¼¼Á¶ÀºÇǺΰú) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 10:05~10:15 Identification of dermal melanin-containing cells in postinflammatory hyperpigmentation  È²Á¤¹Î(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 10:15~10:25 Age-dependent sequential increase of senescent cells in the skin  ±èÅÂÇü(¾ÆÁÖÀÇ´ë) 
È޽Ġ06-12 Á¦¶ó´½È¦ 10:25~10:55 Coffee Break  () 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 10:55~11:10 Non-immunological factors in vitiligo pathogenesis  ÃÖÁ¾¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 11:10~11:25 Immunologic players involved in disease initiation and maintenance  ÀÌÈñÁ¤(Â÷ÀÇ°ú´ëÇÐ) 
Åä·Ð 06-12 Á¦¶ó´½È¦ 11:25~11:35 Q&A  ¹ÚöÁ¾À̵¿À±ÃÖÁ¾¿øÀÌÈñÁ¤(°¡Å縯ÀǴ뼺±Õ°üÀÇ´ë¼­¿ïÀÇ´ëÂ÷ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 11:35~11:43 Genetic association between NALP1 polymorphism and non-segmental vitiligo in the Korean population  ÀÌ»óµÎ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 11:43~11:52 Association of adenotonsillar disease and adenotonsillectomy with the development of Vitiligo: A nationwide population-based cohort study in Korea  ÀÌÀÏÀç(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 11:52~12:00 Effects of vitiligo serum-derived exosomes and stem cell-derived exosomes on autophagy, oxidative stress, and inflammation in human keratinocytes  ±èÁøö(ÇѸ²ÀÇ´ë) 
½Ä»ç 06-12 Á¦¶ó´½È¦ 12:00~13:40 Á¡½É½Ä»ç  () 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 13:40~13:55 Treatment for stopping disease progression in active vitiligo: medication options and usages  Á¤±âÇå(°æÈñÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 13:55~14:10 The ABC of phototherapy practice in vitiligo: Selection of NBUVB or excimer laser, initial and maximum dose, treatment duration for determination of treatment failure or others  ±è´ë¼®(¿¬¼¼¿µÇǺΰú) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 14:10~14:25 Tips of skin grafting for vitiligo: ¡°Just do it¡± according to the lecture  ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú) 
Åä·Ð 06-12 Á¦¶ó´½È¦ 14:25~14:35 Q&A  ±è±âÈ£±èÅÂÈï½ÅÁ¤ÇöÁ¤±âÇå±è´ë¼®¹èÁ¤¹Î(µ¿¾ÆÀÇ´ëÈ­ÀÌÆ®¶óÀÎÇǺΰúÀÎÇÏÀÇ´ë°æÈñÀǴ뿬¼¼¿µÇǺΰúÈúÇϿ콺ÇǺΰú) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 14:35~14:43 New classification and treatment outcome of hand vitiligo: A cluster analysis  ÁÖÇöÁ¤(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 14:43~14:52 The efficacy of cyclosporine in progressive vitiligo  Çѽ°æ(¿ìÅÂÇÏÇѽ°æÇǺΰú) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 14:52~15:00 Treatment results of tissue grafting in vitiligo: A single-center retrospective analysis  ³ë¿ø¼®(¿¬¼¼ÀÇ´ë) 
È޽Ġ06-12 Á¦¶ó´½È¦ 15:00~15:30 Coffee break and Poster viewing  () 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 15:30~15:45 Partial unilateral lentiginosis, nevus spilus  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 15:45~16:00 Alternative treatment options for melasma refractory to laser toning  ÃÖ¼ö¿µ(º¦¿¤ÇǺΰú) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 16:00~16:15 ´Ù¾çÇÑ ÀÓ»ó¾ç»ó¿¡¼­ÀÇ ABNOM Ä¡·á ÀÓ»ó À̾߱⠠¹ÚÀÏÁß(´õÇǺΰú) 
Åä·Ð 06-12 Á¦¶ó´½È¦ 16:15~16:30 Q&A  ±è¹æ¼øÀ强ÀºÀÌÁ¾ÈñÀ¯È­Á¤ÃÖ¼ö¿µ¹ÚÀÏÁß(¿¡½º¿£À¯ÇǺΰú¿ï»êÀǴ뼺±Õ°üÀÇ´ë°í·ÁÀǴ뺦¿¤ÇǺΰú´õÇǺΰú) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 16:30~16:40 Treatment of partial unilateral lentiginosis using medium-fluence 1064 nm picosecond Nd-Yag Laser  ¼º¼³È­(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 16:40~16:50 The efficacy and safety of low-fluence 1064nm picosecond Nd-Yag laser compared with low-fluence photoacoustic therapy pulsed mode 1064nm Q-switched Nd-Yag laser for treatment of melasma: A prospective split-face study  À̼ҿ¬(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 16:50~17:00 Clinical benefit of moisturizer for improvement of post-inflammatory hyperpigmentation in atopic dermatitis lesion: A comparative study with the combination of topical tacrolimus  Á¤¿¬ÁÖ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 17:00~17:10 Split-face comparative study of 785-nm picosecond Nd-Yag laser and precision cryotherapy combination treatment for facial benign pigmented lesions  °í¿µ±Ô(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 06-12 Á¦¶ó´½È¦ 17:10~17:50 Vitiligo: From pathogenesis, with a focus on the innate immunity, to therapeutic perspectives  Thierry Passeron(Department of Dermatology Université Côte d¡¯Azur in Nice France) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦2Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ½ÉÆ÷Áö¾ö : 2022-06-12""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °í·Á´ëÇб³±¸·Îº´¿ø ¼øȯ±â³»°ú Á¦14ȸ KOALA(KOrea guro cArdiovascuLAr center) Symposium 2022 : 2022-06-12
´ÙÀ½±Û ´ëÇѺ¸Á¶»ý½ÄÇÐȸ Á¦2Â÷ ÃʽÉÀÚ¸¦ À§ÇÑ º¸Á¶»ý½Ä¼ú (ART) ±³À°°­Á : 2022-06-12
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
60 ºÎ»ê 2018³â ´ëÇѼÒÈ­±â¿¬°üÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2018-08-18 0 675 2018-07-28
59 ¼­¿ï ´ëÇÑ»êºÎÀΰúÀÇ»çȸ&Çѱ¹¹ß»ý»ý¹°ÇÐȸ Joint Symposium : 2018-08-18 0 1,080 2018-07-28
58 ¼­¿ï ´ëÇѺ´¸®ÇÐȸ 8th Ç÷¾×º´¸® ¿¬¼ö±³À° : 2018-08-18 0 706 2018-07-28
57 ¼­¿ï ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18 0 835 2018-07-28
56 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ 2018³âµµ Á¦2Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-17 0 857 2018-07-28
55 °­¿ø ´ëÇѽÉÀåÇÐȸ Ç÷°ü¿¬±¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö : 2018-08-17 0 1,286 2018-07-28
54 ¼­¿ï Á߾Ӵ뺴¿ø »êºÎÀΰú žÆÃÊÀ½ÆÄ ¿¬¼Ó°­Á : 2018-08-16 0 659 2018-07-28
53 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À°(ÈĵÎÁúȯ) : 2018-08-16 0 728 2018-07-28
52 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè ¼ö°¡°áÁ¤ : 2018-08-16 0 865 2018-07-28
51 ¼­¿ï Çѱ¹¿ªÇÐȸ Biomarker ¸¦ ÀÌ¿ëÇÑ ¿¬±¸ ¼³°è¿Í ºÐ¼® : 2018-08-14 0 1,277 2018-07-28
50 ¼­¿ï Á¦240ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ : 2018-08-14 0 423 2018-07-28
49 ¼­¿ï Çѱ¹¿ªÇÐȸ MR ±â¹Ý À¯Àüü ¿ªÇבּ¸¿Í °ø°ø°Ç°­ÀÚ·á ±â¹Ý Outcome research : 2018-08-13 0 646 2018-07-28
48 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø 2018 Catholic Orthopedic Symposium II - Foot & Ankle, Hip, Knee - : 2018-08-12 0 1,100 2018-07-28
47 ¼­¿ï 2018 ´ëÇÑÈäºÎ¿µ»óÀÇÇÐȸ ¿¬¼ö°­Á : 2018-08-12 0 539 2018-07-28
46 ¼­¿ï 2018 Á¦ 2ȸ ´ëÇѺ¹¸·¾ÏÇÐȸ ±¹Á¦½ÉÆ÷Áö¾ö : 2018-08-11 0 1,421 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷